A shortage of new money is likely to drive more and more life sciences companies into mergers and acquisitions [1], say some of the industry's top analysts. Money raised from IPOs, venture capital companies and stock sales dropped to a meager $6.5 billion in the first half of this year, less than a third of the amount posted in the first half of last year. And they cited Invitrogen's acquisition of Applied Biosystems as a prime example of what lies ahead.
Two bright spots: Expanding markets in China and India [2] will help the field as the U.S. economy softens and federal funding of the NIH will grow regardless of who is elected.
- check out the AP report [3]
Related Articls:
Biotech M&A has yet to reach its peak [1]
Should Pharma take the M&A cure? [4]
Pharma goes mad for biotech deals [5]
Burrill bullish on M&As [6]
M&A activity heats up as biotech IPOs struggle [7]
Links:
[1] http://www.fiercebiotech.com/story/biotech-ma-has-yet-to-reach-its-peak/2008-05-09
[2] http://www.fiercepharma.com/story/emerging-markets-drive-global-growth/2008-04-16
[3] http://www.boston.com/business/healthcare/articles/2008/07/02/analysts_expect_more_mergers_in_life_sciences/
[4] http://www.fiercepharma.com/story/should-pharma-take-m-cure/2007-10-01
[5] http://www.fiercepharma.com/story/pharma-goes-mad-biotech-deals/2007-12-21
[6] http://www.fiercebiotech.com/story/burrill-bullish-m/2007-12-03
[7] http://www.fiercebiotech.com/story/ma-activity-heats-up-as-biotech-ipos-struggle/2007-02-23